Prognostic factors, efficacy, and toxicity of involved-node stereotactic body radiation therapy for lymph node oligorecurrent prostate cancer : An investigation of 117 pelvic lymph nodes.
Elective nodal radiotherapy
Metastatis-directed prostate cancer therapy
Oligomestasis
Pelvic lymph-node oligorecurrence
Salvage prostate radiotherapy
Stereotactic ablative body radiotherapy
Journal
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
ISSN: 1439-099X
Titre abrégé: Strahlenther Onkol
Pays: Germany
ID NLM: 8603469
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
received:
21
06
2021
accepted:
17
10
2021
pubmed:
11
11
2021
medline:
23
7
2022
entrez:
10
11
2021
Statut:
ppublish
Résumé
The optimal radiotherapy regimen is not yet defined in the setting of oligorecurrent prostate cancer (oligorPC). There is evidence of high variability in treatment protocols among different centers worldwide, and no international consensus guidelines on treatment volumes, radiation schedules, and techniques. The purpose of the present retrospective study is to evaluate the efficacy and safety of involved-pelvic-node stereotactic body radiotherapy (SBRT) for oligorPC. Patients with pelvic node oligorPC following primary surgery, radical radiotherapy, or salvage radiotherapy for biochemical or local relapse of prostate cancer who underwent involved-node SBRT with biological effective dose (BED) > 100 Gy, with or without concurrent and adjuvant androgen deprivation therapy (ADT), were retrospectively evaluated. Biochemical progression-free survival (bPFS), distant progression-free survival (DPFS), overall survival (OS), possible prognostic factors, and toxicity outcomes were investigated. From November 2012 to December 2019, 74 patients fitted the selection criteria. A total of 117 lesions were treated. Median follow-up was 31 months (range 6-89). Concurrent ADT was administered in 58.1% of patients. The 1‑year, 2‑year, and 3‑year DPFS was 77%, 37%, and 19%, respectively; the 1‑year, 2‑year, and 3‑year OS was 98%, 98%, and 95%, respectively. The presence of a single target lesion was associated with a statistically significant impact on OS. No in-field recurrence occurred. Patients who reached early prostate-specific antigen (PSA) nadir (< 3 months after SBRT) had a lower 3‑year survival (p = 0.004). The value of PSA nadir after SBRT and the time between primary treatment and SBRT had an impact on bPFS. Concomitant ADT was associated with improved DPFS. No acute or early late (> 6 months) genitourinary and gastrointestinal adverse events of any grade were reported, albeit with relatively short median follow-up. SBRT is a safe and effective treatment for oligorPC, with a 100% local control rate in our series. It is not possible to clearly assess the opportunity to postpone ADT prescription in patients with two or more nodal metastases. The number of secondary lesions, time-to-nadir PSA, PSA nadir value, and the time interval between primary treatment and SBRT were identified as prognostic factors. Future prospective randomized studies are desirable to better understand the still open questions regarding the oligorecurrent prostate cancer state.
Sections du résumé
BACKGROUND
The optimal radiotherapy regimen is not yet defined in the setting of oligorecurrent prostate cancer (oligorPC). There is evidence of high variability in treatment protocols among different centers worldwide, and no international consensus guidelines on treatment volumes, radiation schedules, and techniques. The purpose of the present retrospective study is to evaluate the efficacy and safety of involved-pelvic-node stereotactic body radiotherapy (SBRT) for oligorPC.
MATERIALS AND METHODS
Patients with pelvic node oligorPC following primary surgery, radical radiotherapy, or salvage radiotherapy for biochemical or local relapse of prostate cancer who underwent involved-node SBRT with biological effective dose (BED) > 100 Gy, with or without concurrent and adjuvant androgen deprivation therapy (ADT), were retrospectively evaluated. Biochemical progression-free survival (bPFS), distant progression-free survival (DPFS), overall survival (OS), possible prognostic factors, and toxicity outcomes were investigated.
RESULTS
From November 2012 to December 2019, 74 patients fitted the selection criteria. A total of 117 lesions were treated. Median follow-up was 31 months (range 6-89). Concurrent ADT was administered in 58.1% of patients. The 1‑year, 2‑year, and 3‑year DPFS was 77%, 37%, and 19%, respectively; the 1‑year, 2‑year, and 3‑year OS was 98%, 98%, and 95%, respectively. The presence of a single target lesion was associated with a statistically significant impact on OS. No in-field recurrence occurred. Patients who reached early prostate-specific antigen (PSA) nadir (< 3 months after SBRT) had a lower 3‑year survival (p = 0.004). The value of PSA nadir after SBRT and the time between primary treatment and SBRT had an impact on bPFS. Concomitant ADT was associated with improved DPFS. No acute or early late (> 6 months) genitourinary and gastrointestinal adverse events of any grade were reported, albeit with relatively short median follow-up.
CONCLUSION
SBRT is a safe and effective treatment for oligorPC, with a 100% local control rate in our series. It is not possible to clearly assess the opportunity to postpone ADT prescription in patients with two or more nodal metastases. The number of secondary lesions, time-to-nadir PSA, PSA nadir value, and the time interval between primary treatment and SBRT were identified as prognostic factors. Future prospective randomized studies are desirable to better understand the still open questions regarding the oligorecurrent prostate cancer state.
Identifiants
pubmed: 34757443
doi: 10.1007/s00066-021-01871-5
pii: 10.1007/s00066-021-01871-5
doi:
Substances chimiques
Androgen Antagonists
0
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
700-709Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
Références
Torre LA, Siegel R, Ward EM et al (2016) global cancer incidence and mortality rate and trends: an update. Cancer Epidemiol Biomarkers Prev 25(1):16–27
doi: 10.1158/1055-9965.EPI-15-0578
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac.21492
doi: 10.3322/caac.21492
pubmed: 30207593
Italian Medical Oncology Association (2018) Italian cancer registry by the Italian Medical Oncology Association
Parker WP, Davis BJ, Park SS et al (2017) Identification of site-specific recurrence following primary radiation therapy for prostate cancer using C‑11 choline positron emission tomography/computed tomography: a nomogram for predicting extrapelvic disease. Eur Urol 71:340–348
doi: 10.1016/j.eururo.2016.08.055
Alongi F, Arcangeli S, Filippi AR et al (2012) Review and uses of stereotactic body radiation therapy for oligometastases. Oncologist 17(8):1100–1107
doi: 10.1634/theoncologist.2012-0092
Calais J, Czernin J, Cao M et al (2018) 68Ga-PSMA-11 PET/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng/mL: impact on salvage radiotherapy planning. J Nucl Med 59:230–237
doi: 10.2967/jnumed.117.201749
Devos G, De Meerleer G, Joniau S (2019) Have we entered the era of imaging before salvage treatment for recurrent prostate cancer? Eur Urol 76:265–267
doi: 10.1016/j.eururo.2019.04.016
Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG et al (2016) Sensitivity, specificity, and predictors of positive (68)Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol 70:926–937
doi: 10.1016/j.eururo.2016.06.021
Lancia A, Zilli T, Achard V et al (2019) Oligometastatic prostate cancer: the game is afoot. Cancer Treat Rev 73:84–90
doi: 10.1016/j.ctrv.2019.01.005
Phillips R, Shi WY, Deek M et al (2020) Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol 6:650
doi: 10.1001/jamaoncol.2020.0147
Panje C, Zilli T, Pra AD et al (2019) Radiotherapy for pelvic nodal recurrences after radical prostatectomy: patient selection in clinical practice. Radiat Oncol 14:177
doi: 10.1186/s13014-019-1383-0
De Bruycker A, Lambert B, Claeys T, Delrue L, Mbah C, De Meerleer G et al (2017) Prevalence and prognosis of low-volume, oligorecurrent, hormone-sensitive prostate cancer amenable to lesion ablative therapy. BJU Int 120:815–821
doi: 10.1111/bju.13938
Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13:8–10
doi: 10.1200/JCO.1995.13.1.8
Achard V, Bottero M, Rouzaud M et al (2020) Radiotherapy treatment volumes for oligorecurrent nodal prostate cancer: a systematic review. Acta Oncol 59(10):1224–1234. https://doi.org/10.1080/0284186X.2020.1775291
doi: 10.1080/0284186X.2020.1775291
pubmed: 32536241
De Bruycker A, Spiessens A, Dirix P et al (2020) PEACE V—Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial. BMC Cancer 20(1):406
doi: 10.1186/s12885-020-06911-4
Ost P, Jereczek-Fossa BA, As NV et al (2016) Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naive recurrence: a multi-institutional analysis. Eur Urol 69:9–12
doi: 10.1016/j.eururo.2015.07.004
Phillips R, Shi WY, Deek M et al (2020) Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol 6:650
doi: 10.1001/jamaoncol.2020.0147
Pasqualetti F, Panichi M, Sollini M et al (2020) (18)F]Fluorocholine PET/CT-guided stereotactic body radiotherapy in patients with current oligometastatic prostate cancer. Eur J Nucl Med Mol Imaging 47:185–191
doi: 10.1007/s00259-019-04482-6
Ost P, Reynders D, Decaestecker K et al (2018) Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence:a prospective, randomized, multicenter phase II trial. J Clin Oncol 36:446–453
doi: 10.1200/JCO.2017.75.4853
Siva S, Bressel M, Murphy DG et al (2018) Stereotactic abative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial. Eur Urol 74:455–462
doi: 10.1016/j.eururo.2018.06.004
Jereczek-Fossa BA, Fanetti G, Fodor C et al (2017) Salvage stereotactic body radiotherapy for isolated lymph node recurrent prostate cancer: single institution series of 94 consecutive patients and 124 lymph nodes. Clin Genitourin Cancer 15:e623–e632
doi: 10.1016/j.clgc.2017.01.004
Decaestecker K, De Meerleer G, Lambert B et al (2014) Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. Radiat Oncol 9:135
doi: 10.1186/1748-717X-9-135
Jereczek-Fossa BA, Beltramo G, Fariselli L et al (2012) Robotic image guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys 82:889–897
doi: 10.1016/j.ijrobp.2010.11.031
Casamassima F, Masi L, Menichelli C et al (2011) Efficacy of eradicative radiotherapy for limited nodal metastases detected with choline PET scan in prostate cancer patients. Tumori 97:49–55
doi: 10.1177/030089161109700110
Kneebone A, Hruby G, Ainsworth H et al (2018) Stereotactic body radiotherapy for oligometastatic prostate cancer detected via prostate-specific membrane antigen positron emission tomography. Eur Urol Oncol 1:531–537
doi: 10.1016/j.euo.2018.04.017
Soldatov A, von Klot CAJ, Walacides D et al (2019) Patterns of progression after 68Ga-PSMA-ligand PET/CT-guided radiation therapy for recurrent prostate cancer. Int J Radiat Oncol Biol Phys 103:95–104
doi: 10.1016/j.ijrobp.2018.08.066
Perera M, Papa M, Roberts M et al (2020) Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol 77(4):403–417
doi: 10.1016/j.eururo.2019.01.049
Berkovic P, De Meerleer G, Delrue L et al (2013) Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation, therapy. Clin Genitourin Cancer 11:27–32
doi: 10.1016/j.clgc.2012.08.003
Schick U, Jorcano S, Nouet P, Rouzaud M, Vees H, Zilli T et al (2013) Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases. Acta Oncol 52:1622–1628
doi: 10.3109/0284186X.2013.764010
Ponti E, Lancia A, Ost P, Trippa F, Triggiani L, Detti B et al (2017) Exploring all avenues for radiotherapy in oligorecurrent prostate cancer disease limited to lymph nodes: a systematic review of the role of stereotactic body radiotherapy. Eur Urol Focus 3:538–544
doi: 10.1016/j.euf.2017.07.006
Carrie C, Hasbini A, de Laroche G et al (2016) Salvage radiotherapy with or without short-term hormone therapy for rising prostatespecific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol 17:747–756
doi: 10.1016/S1470-2045(16)00111-X
Shipley WU, Seiferheld W, Lukka HR et al (2017) Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med 376:417–428
doi: 10.1056/NEJMoa1607529
Pollack A, Balogh AG, Low D et al (2018) Short term androgen deprivation therapy without or with pelvic lymph node treatment added to prostate bed only salvage radiation therapy: the NRG Oncology/RTOG 0534 SPPORT trial. ASTRO 102:1605
Ost P, Reynders D, Decaestecker K et al (2018) Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol 36(5):446–453
doi: 10.1200/JCO.2017.75.4853
Park Y, Park HJ, Jang WI, Jeong BK, Kim H‑J, Chang AR (2018) Long-term results and PSA kinetics after robotic SBRT for prostate cancer: multicenter retrospective study in Korea (Korean Radiation Oncology group study 15-01). Radiat Oncol 13(1):230
doi: 10.1186/s13014-018-1182-z
Sasaki T, Onishi T, Hoshina A (2011) Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis. Prostate Cancer Prostatic Dis 14(3):248–252
doi: 10.1038/pcan.2011.14
Hori S, Jabbar T, Kachroo N et al (2011) Outcomes and predictive factors for biochemical relapse following primary androgen deprivation therapy in men with bone scan negative prostate cancer. J Cancer Res Clin Oncol 137:235–241
doi: 10.1007/s00432-010-0877-9
Arai Y, Yoshiki T, Yoshida O (1990) Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer. J Urol 144:1415–1419
doi: 10.1016/S0022-5347(17)39757-4
Yeung F, Li X, Ellett J et al (2000) Regions of prostate-specific antigen (PSA) promoter confer androgen-independent expression of PSA in prostate cancer cells. J Biol Chem 275:40846–40855
doi: 10.1074/jbc.M002755200
Onishi T, Yamakawa K, Franco OE et al (2001) Mitogen-activated protein kinase pathway is involved in alpha 6 integrin gene expression in androgen-independent prostate cancer cell: role of proximal Sp1 consensus sequence. Biochim Biophys Acta 14728:1–1
Choueiri TK, Xie W, d’Amico AV et al (2009) Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. Cancer 115:981–987
doi: 10.1002/cncr.24064